Clinical Trial Search

Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months

Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants

Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants

Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants

Primary: Overall Survival — 12; 11; 13 participants

Primary: RR — 15 Participants

Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants

Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants

Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders

Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants

Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months

Primary: Overall Survival (OS) — 11.96 Months

Primary: Complete Pathologic Response Rate — 14 percentage of participants

Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473

Primary: Response Rate — 0 percentage of patients responding

Primary: Objective Response Rate — 15 Participants

Primary: Best Objective Response Rate (bORR) — 61; 50 Percentage of participants

Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants

Primary: Months of Progression-free Survival (PFS) — 7.6 months — p=0.02

Primary: Maximum Tolerated Dose (MTD) — 50 mg/m^2

Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants

Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed…

Primary: Progression Free Survival — 7.8 months

Primary: Overall Survival — 13.4 month

Primary: Progression-free Survival (PFS) — 5.257 months

Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months

Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants

Primary: Objective Response Rate (ORR) — 9.7; 6.9 percentage of participants — p=0.8